Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has provided an update.
Lepu Biopharma Co., Ltd. has entered into a New Procurement Framework Agreement with Lepu Medical to continue their ongoing transactions, which include the supply of raw materials and services for clinical trials and employee welfare. This agreement, effective from January 1, 2026, to December 31, 2026, aims to ensure the continuation of procurement activities under normal commercial terms, with provisions for renewal subject to legal and regulatory requirements.
The most recent analyst rating on (HK:2157) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on Lepu Biopharma Co. Ltd. Class H stock, see the HK:2157 Stock Forecast page.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and procurement of pharmaceutical products, clinical trial materials, and related services. The company is connected with Lepu Medical, which holds a significant share in Lepu Biopharma.
Average Trading Volume: 14,937,493
Technical Sentiment Signal: Hold
Current Market Cap: HK$10.71B
For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.